Study on Veliparib with or without Radiation, Carboplatin, and Paclitaxel for Stage III Non-Small Cell Lung Cancer

Program Overview

The study aims to find out if the drug veliparib, when combined with radiation therapy and chemotherapy drugs carboplatin and paclitaxel, can better treat stage III non-small cell lung cancer that cannot be surgically removed. Veliparib may help stop tumor growth by blocking certain enzymes. Radiation uses high-energy x-rays to kill cancer cells, while carboplatin and paclitaxel work to stop cancer cells from growing and spreading. Researchers want to see if adding veliparib makes these treatments more effective.

Description

This study is divided into two phases. In Phase I, researchers will determine the safest dose of veliparib when used with standard chemotherapy and radiation therapy. In Phase II, they will compare the effectiveness of the treatment with and without veliparib.

During Phase I, patients will receive radiation therapy five days a week for six weeks, along with veliparib taken orally twice a day and chemotherapy drugs carboplatin and paclitaxel given through an IV. If the cancer does not progress, patients will continue with additional treatment cycles.

In Phase II, patients will be randomly assigned to one of two groups. One group will receive the same treatment as in Phase I, while the other group will receive a placebo instead of veliparib, along with the same chemotherapy and radiation therapy.

After completing the study treatment, patients will have follow-up visits every four months for the first two years, then every six months until five years.

Eligibility Criteria

Locations